Q1 2025 Earnings Estimate for Globus Medical, Inc. Issued By Zacks Research (NYSE:GMED)

Globus Medical, Inc. (NYSE:GMED) – Zacks Research lifted their Q1 2025 earnings estimates for Globus Medical in a report issued on Monday, October 7th. Zacks Research analyst R. Department now anticipates that the medical device company will post earnings per share of $0.77 for the quarter, up from their prior forecast of $0.76. The consensus estimate for Globus Medical’s current full-year earnings is $2.84 per share. Zacks Research also issued estimates for Globus Medical’s Q2 2025 earnings at $0.81 EPS, Q4 2025 earnings at $0.82 EPS, FY2025 earnings at $3.21 EPS, Q1 2026 earnings at $0.84 EPS and FY2026 earnings at $3.78 EPS.

Globus Medical (NYSE:GMED) last released its quarterly earnings results on Tuesday, August 6th. The medical device company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.07. Globus Medical had a net margin of 1.82% and a return on equity of 8.70%. The company had revenue of $629.69 million for the quarter, compared to analyst estimates of $615.33 million. During the same period last year, the firm earned $0.63 earnings per share. The firm’s revenue was up 115.9% on a year-over-year basis.

Several other analysts have also commented on GMED. Barclays lifted their price objective on shares of Globus Medical from $85.00 to $93.00 and gave the stock an “overweight” rating in a research report on Thursday, August 8th. Royal Bank of Canada lifted their price objective on shares of Globus Medical from $78.00 to $80.00 and gave the stock an “outperform” rating in a research report on Tuesday. Needham & Company LLC reaffirmed a “hold” rating on shares of Globus Medical in a research report on Wednesday, August 7th. BTIG Research lifted their price objective on shares of Globus Medical from $75.00 to $77.00 and gave the stock a “buy” rating in a research report on Wednesday, August 28th. Finally, Morgan Stanley boosted their price target on shares of Globus Medical from $67.00 to $71.00 and gave the company an “equal weight” rating in a research report on Monday, July 15th. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $77.40.

Globus Medical Price Performance

GMED opened at $70.06 on Wednesday. The company’s 50-day moving average is $70.48 and its 200 day moving average is $64.94. Globus Medical has a fifty-two week low of $43.38 and a fifty-two week high of $74.21. The firm has a market capitalization of $9.48 billion, a P/E ratio of 109.47, a PEG ratio of 1.97 and a beta of 1.17.

Institutional Investors Weigh In On Globus Medical

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GMED. Select Equity Group L.P. bought a new stake in Globus Medical during the 2nd quarter valued at $91,711,000. Millennium Management LLC raised its holdings in Globus Medical by 1,171.5% during the 2nd quarter. Millennium Management LLC now owns 1,363,834 shares of the medical device company’s stock valued at $93,409,000 after buying an additional 1,256,570 shares during the last quarter. Magnetar Financial LLC raised its holdings in Globus Medical by 198.6% during the 1st quarter. Magnetar Financial LLC now owns 1,689,287 shares of the medical device company’s stock valued at $90,613,000 after buying an additional 1,123,540 shares during the last quarter. Motley Fool Asset Management LLC raised its holdings in Globus Medical by 1,263.7% during the 1st quarter. Motley Fool Asset Management LLC now owns 848,164 shares of the medical device company’s stock valued at $45,496,000 after buying an additional 785,970 shares during the last quarter. Finally, Burgundy Asset Management Ltd. raised its holdings in Globus Medical by 46.1% during the 1st quarter. Burgundy Asset Management Ltd. now owns 2,479,837 shares of the medical device company’s stock valued at $133,018,000 after buying an additional 782,285 shares during the last quarter. 95.16% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Leslie V. Norwalk sold 1,000 shares of the company’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $70.00, for a total value of $70,000.00. Following the completion of the sale, the director now owns 16,419 shares of the company’s stock, valued at approximately $1,149,330. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Ann D. Rhoads sold 15,000 shares of the company’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $70.36, for a total transaction of $1,055,400.00. Following the completion of the sale, the director now directly owns 42,884 shares in the company, valued at $3,017,318.24. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Leslie V. Norwalk sold 1,000 shares of the company’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $70.00, for a total transaction of $70,000.00. Following the sale, the director now owns 16,419 shares of the company’s stock, valued at $1,149,330. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 18.54% of the stock is owned by corporate insiders.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.